Ophthalmologica最新文献

筛选
英文 中文
Macular Microcirculation by OCT-A in Relation to Diabetic Peripheral Neuropathy and Ocular Surface Biomarkers: A Cross-Sectional Study. 黄斑微循环OCT-A与糖尿病周围神经病变和眼表生物标志物的关系:一项横断面研究。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-11-14 DOI: 10.1159/oph/aeeag020
Pau Cid-Bertomeu, Magí Vilaltella, Laura Capilla, Valentin Huerva
{"title":"Macular Microcirculation by OCT-A in Relation to Diabetic Peripheral Neuropathy and Ocular Surface Biomarkers: A Cross-Sectional Study.","authors":"Pau Cid-Bertomeu, Magí Vilaltella, Laura Capilla, Valentin Huerva","doi":"10.1159/oph/aeeag020","DOIUrl":"https://doi.org/10.1159/oph/aeeag020","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the association between diabetic peripheral neuropathy (DPN), corneal sensitivity, and tear matrix metalloproteinase-9 (MMP-9) with macular microcirculatory parameters assessed by optical coherence tomography angiography (OCT-A) in patients with diabetes mellitus.</p><p><strong>Methods: </strong>This cross-sectional observational study included 158 eyes of 79 patients with type 1 or type 2 diabetes mellitus (DM) undergoing routine retinopathy screening at a single tertiary centre. Superficial capillary plexus vessel density and foveal avascular zone (FAZ) parameters (area, perimeter, and circularity index) were obtained by OCT-A (Cirrus 6000, AngioPlex®, Carl Zeiss Meditec). Corneal sensitivity was measured with the Brill esthesiometer and tear MMP-9 was assessed with the InflammaDry test. DPN was confirmed by electroneuromyography. Linear mixed models with random intercept per patient were applied to account for bilateral data.</p><p><strong>Results: </strong>Among OCT-A parameters, vessel density and FAZ area and perimeter did not show significant association with DPN status, MMP-9 positivity, or corneal sensitivity. FAZ circularity showed a significant negative association with DPN in the multivariable model (β = -0.07; p = 0.021) and with corneal sensitivity in the linear mixed model (β = 0.01; p = 0.049), but was not associated with MMP-9 status (p = 0.691). No OCT-A parameter was associated with MMP-9 in any analysis.</p><p><strong>Conclusions: </strong>FAZ circularity was independently associated with DPN and with reduced corneal sensitivity, suggesting a potential retinal correlate of neurovascular damage in diabetes; however, this is a model-dependent, exploratory finding requiring prospective confirmation. No OCT-A parameter was associated with MMP-9 status, suggesting compartmental dissociation between anterior segment inflammation and posterior segment microvascular status at this disease stage.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149409371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MACULAR STRUCTURE AND FUNCTION IN RETINAL DETACHMENT COMPLICATED BY PROLIFERATIVE VITREORETINOPATHY. 视网膜脱离合并增生性玻璃体视网膜病变的黄斑结构与功能。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-10-27 DOI: 10.1159/oph/aeeag019
Rodrigo Anguita, Peng Yong Sim, Lorenzo Ferro Desideri, Moritz Joachim Schmid, Philip J Banerjee, Martin Zinkernagel, David G Charteris
{"title":"MACULAR STRUCTURE AND FUNCTION IN RETINAL DETACHMENT COMPLICATED BY PROLIFERATIVE VITREORETINOPATHY.","authors":"Rodrigo Anguita, Peng Yong Sim, Lorenzo Ferro Desideri, Moritz Joachim Schmid, Philip J Banerjee, Martin Zinkernagel, David G Charteris","doi":"10.1159/oph/aeeag019","DOIUrl":"https://doi.org/10.1159/oph/aeeag019","url":null,"abstract":"<p><strong>Introduction: </strong>Macular structural changes after surgery for rhegmatogenous retinal detachment (RRD) complicated by proliferative vitreoretinopathy (PVR) remain poorly characterised. The aim of this study was to evaluate longitudinal macular structural changes on optical coherence tomography (OCT) and their relationship to visual function over 12 months in eyes undergoing pars plana vitrectomy (PPV) with silicone oil tamponade for PVR-related RRD.</p><p><strong>Methods: </strong>Post-hoc analysis from a phase IIIb, single-centre, participant-masked, prospective, randomised controlled trial of slow-release dexamethasone in PVR-related RRD conducted at Moorfields Eye Hospital. One hundred and thirty-nine (139) eyes of 139 patients undergoing PPV with silicone oil tamponade for RRD with confirmed PVR-C were included. Spectral-domain OCT imaging and best-corrected visual acuity (BCVA, LogMAR) were obtained preoperatively and at 10 days, 6 months, and 12 months postoperatively. Retinal-layer thicknesses were obtained by manual segmentation and 13 qualitative biomarkers were graded. Univariable regression and Firth penalised multivariable logistic regression were used to identify early structural predictors of 12-month BCVA.</p><p><strong>Results: </strong>Central retinal thickness (CRT) increased significantly from 314.9 µm at 10 days to 370.9 µm at 12 months (p < 0.0001). The outer plexiform layer and outer nuclear layer showed dynamic changes over time. The proportion of eyes with epiretinal membrane (ERM) rose from 22.1% at 10 days to 41.2% at 6 months (p=0.001) and 49.6% at 12 months (p=0.011 versus 6 months), and cystoid macular oedema (CMO) increased from 20.7% to 52.2% (p<0.0001) and 62.6% (p = 0.029). Mean BCVA improved from 1.68 LogMAR preoperatively to 1.06 LogMAR at 10 days (p < 0.0001), with no significant further change to 0.92 LogMAR at 12 months. In univariable analysis, retinal pigment epithelium (RPE) thickness, outer retinal layer thickness, gross full-thickness retinal disruption, disrupted ellipsoid and external limiting membrane, absence of a foveal bulge, subretinal PVR and persistent subretinal macular fluid at 10 days were associated with poorer 12-month BCVA (all p < 0.05). In the multivariable model, 10-day BCVA (adjusted odds ratio [aOR] 3.52, 95% CI 1.31-11.2) and gross full-thickness retinal disruption (aOR 10.51, 95% CI 1.16-1391) remained independently associated with moderate visual impairment at 12 months (BCVA worse than 6/38; LogMAR > 0.80), with an area under the receiver operating characteristic curve of 0.71.</p><p><strong>Conclusions: </strong>Macular structural changes after surgery for PVR-related RRD reflect extensive cellular remodelling with progressive development of ERM and CMO. Early (10-day) postoperative OCT findings are associated with 12-month visual outcome and may help inform prognosis in PVR-related RRD.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149288189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Intravitreal Faricimab for Diabetic Macular Edema and Analysis of Influencing Factors. 法利西单抗玻璃体内治疗糖尿病性黄斑水肿的疗效及影响因素分析。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-10-16 DOI: 10.1159/oph/aeeag017
Gong Chen, Zhaohua Zhang, Fanling Meng, Yuechao Zhao, Wen Zheng
{"title":"Efficacy of Intravitreal Faricimab for Diabetic Macular Edema and Analysis of Influencing Factors.","authors":"Gong Chen, Zhaohua Zhang, Fanling Meng, Yuechao Zhao, Wen Zheng","doi":"10.1159/oph/aeeag017","DOIUrl":"https://doi.org/10.1159/oph/aeeag017","url":null,"abstract":"<p><strong>Objective: </strong> To evaluate the efficacy and safety of intravitreal faricimab administered under a treat-and-extend (T&E) strategy for DME in a real-world clinical setting, and to analyze factors associated with visual acuity benefits and durability of disease control during interval extension.</p><p><strong>Methods: </strong> This single-center, retrospective cohort study included 170 patients (170 eyes) with diabetic macular edema who initiated intravitreal faricimab treatment between January 2024 and December 2024 and completed at least 12 months of follow-up. Only one eye per patient was included in the analysis. All included eyes completed a three-dose monthly loading phase and were subsequently managed using a faricimab-based treat-and-extend regimen. The primary efficacy endpoints were changes in best-corrected visual acuity (BCVA, ETDRS letters) and central subfield thickness (CST) at 12 months. Key secondary T&E-related endpoints included the total number of injections within 12 months, the maximum treatment interval achieved by month 12, and the proportion of eyes reaching extension intervals of ≥12 and ≥16 weeks. Multivariable linear regression and Cox proportional hazards regression were used to identify exploratory factors associated with visual acuity improvement and time to treatment interval shortening.</p><p><strong>Results: </strong> At 12 months, mean BCVA improved by 9.7 ± 11.5 letters and mean CST decreased by 191.0 ± 135.0 µm (both P < 0.001); 50.0% gained ≥10 letters and 64.7% achieved a dry macula (CST < 300 µm). In multivariable regression, 1-month CST reduction showed the strongest positive association with BCVA gain (B = 0.48 per 100 µm decrease, β = 0.41, P < 0.001), while baseline HbA1c, baseline CST, and ellipsoid zone impairment were negatively associated. Higher baseline HbA1c, CST ≥500 µm, and EZ impairment were associated with interval shortening during the maintenance phase. No serious adverse events occurred.</p><p><strong>Conclusion: </strong> In real-world DME treated with a T&E faricimab regimen, patients achieve sustained functional and anatomical improvements with a favorable safety profile. Twelve-month outcomes and treatment durability were associated with baseline metabolic control, anatomical disease severity, and early CST response, supporting individualized monitoring during treat-and-extend management.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Influence of Molecular Weight on the Optical Parameters of Silicone Oil Endotamponades for Vitreoretinal Surgery. 分子量对玻璃体视网膜手术用硅油内填塞物光学参数的影响。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-10-15 DOI: 10.1159/oph/aeeag016
Niklas Junker, Bryan Calder Ackermann, Sabrina Wohlfart, Gerd Uwe Auffarth, Philipp Uhl, Victor Aristide Augustin, Grzegorz Łabuz, Maximilian Hammer
{"title":"The Influence of Molecular Weight on the Optical Parameters of Silicone Oil Endotamponades for Vitreoretinal Surgery.","authors":"Niklas Junker, Bryan Calder Ackermann, Sabrina Wohlfart, Gerd Uwe Auffarth, Philipp Uhl, Victor Aristide Augustin, Grzegorz Łabuz, Maximilian Hammer","doi":"10.1159/oph/aeeag016","DOIUrl":"10.1159/oph/aeeag016","url":null,"abstract":"<p><strong>Introduction: </strong>Silicone oil, more specifically polydimethylsiloxane (PDMS) of different molecular weight, is an established endotamponade in vitreoretinal surgery. As emulsification is a feared complication of their intraocular use, high-molecular weight compounds (HMWCs) may be added to modify their physicochemical properties lowering emulsification tendency. However, the optical properties of various HMWCs, as well as blends of silicone oils with different fractions of HMWC have never been studied in a controlled laboratory setting and compared with each other. Optical parameters, such as forward light scattering and turbidity, may indicate intermolecular interactions among PDMS fractions with varying molecular weights.</p><p><strong>Methods: </strong>Blends of Siluron 1,000 and different HMWCs in various ratios were created. Viscosities of the pure HMWC components were 60,000 mPas, 100,000 mPas, and 2,500,000 mPas, respectively. Mixtures of Siluron 1,000 with 10%, 30% and 90% HWMC component were created. Light scattering of these blends and the raw components was quantified using a custom-made C-Quant straylight meter and turbidity was quantified with an ISO-normed turbidity meter. Light scattering and turbidity were compared between the different mixtures and the raw materials. Additionally, measurement of Dynamic Light Scattering (DLS) using a Zetasizer was performed to quantify the formation of possible particle-like HMWC aggregates.</p><p><strong>Results: </strong>Turbidity of PDMS showed a molecular weight-associated increase with the highest turbidity values appearing for pure 2,500,000 mPas HMWC-PDMS. For mixtures of Siluron 1,000 with 100,000 mPas and 2,500,000 mPas HMWC-PDMS, an increased turbidity was observed when the HMWC component exceeded 10%. Forward light scattering values were very low for all tested samples, slightly increased values were only detectable for mixtures with a proportion of 90% HMWC components. DLS revealed a concentration- and molecular weight dependent appearance of particle-like phenomena.</p><p><strong>Conclusion: </strong>Although there was no evidence of clinically relevant optical disturbances for all tested substances, the molecular-weight dependent optical properties of HMWC-blends may be attributed to the presence of optically active particles when mixtures exceed a 10% proportion of high-molecular weight components, specifically for 100,000 and 2,500,000 mPas HWMC PDMS. This finding may indicate suboptimal solubility and compromised intermolecular interaction.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149195978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated Guidelines for the Management of Neovascular Age-Related Macular Degeneration by the European Society of Retina Specialists. 欧洲视网膜专家协会(EURETINA)更新了新血管性年龄相关性黄斑变性管理指南。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-10-12 DOI: 10.1159/oph/aeeag010
Anat Loewenstein, Martin S Zinkernagel, Reinier O Schlingemann, Francesco Bandello, Camiel J F Boon, Ursula Schmidt-Erfurth, Nicole Eter, Caroline C W Klaver, Patricia Udaondo, Sandrine A Zweifel, Adnan Tufail, Frank G Holz
{"title":"Updated Guidelines for the Management of Neovascular Age-Related Macular Degeneration by the European Society of Retina Specialists.","authors":"Anat Loewenstein, Martin S Zinkernagel, Reinier O Schlingemann, Francesco Bandello, Camiel J F Boon, Ursula Schmidt-Erfurth, Nicole Eter, Caroline C W Klaver, Patricia Udaondo, Sandrine A Zweifel, Adnan Tufail, Frank G Holz","doi":"10.1159/oph/aeeag010","DOIUrl":"10.1159/oph/aeeag010","url":null,"abstract":"<p><p>Since the publication in 2014 of the original EURETINA guidelines for the management of neovascular age-related macular degeneration (nAMD), the treatment landscape for this prevalent and potentially devastating condition has evolved substantially. Along with the introduction of new anti-vascular endothelial growth factor (anti-VEGF) agents and the release of biosimilar agents, anti-VEGF dosing strategies have been refined, and increasing amounts of clinical trial and real-world evidence are available to inform practice. To provide an updated European perspective on nAMD management, the EURETINA panel systematically reviewed European guidelines published since 2014 alongside recent randomized controlled trials and other relevant evidence. Areas of broad consensus across guidelines were identified, including the importance of early diagnosis and prompt initiation of anti-VEGF therapy, and the central role of optical coherence tomography (OCT) in both diagnosis and monitoring. Treat-and-extend regimens are now established as the preferred approach for retreatment, with disease activity defined primarily by changes in retinal fluid accumulation detected by OCT imaging. Recommendations also address follow-up, switching or discontinuing therapy, and referral to low vision support services. Incorporating the EURETINA panel's expertise into this synthesis, this update to the EURETINA guidelines for nAMD provides recommendations to guide high-quality, evidence-based care for patients with nAMD across Europe.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subretinal Fluid Correlates with Increased Macular Volume in Diabetic Macular Edema. 视网膜下液与糖尿病性黄斑水肿的黄斑体积增加有关。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-10-08 DOI: 10.1159/oph/aeeag014
Hugo Le Boité, Salomé Maunoury, Aude Couturier
{"title":"Subretinal Fluid Correlates with Increased Macular Volume in Diabetic Macular Edema.","authors":"Hugo Le Boité, Salomé Maunoury, Aude Couturier","doi":"10.1159/oph/aeeag014","DOIUrl":"10.1159/oph/aeeag014","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to determine the prevalence and clinical phenotype of subretinal fluid (SRF) in eyes with diabetic macular edema (DME).</p><p><strong>Methods: </strong>A retrospective study was conducted in treatment-naive patients with DME. The presence of SRF, hard exudates, and cystoid spaces with hyperreflective material on optical coherence tomography B-scans, along with central macular thickness (CMT) in the 1-mm, 3-mm, and 6-mm central areas, was assessed, and the correlation between the presence of SRF and macular thickness was estimated using linear mixed-effects models.</p><p><strong>Results: </strong>Of 101 eyes from 63 patients (49% men, mean age 61.31 ± 9.45 years), 36% had SRF. SRF was significantly and independently associated with macular thickness, with higher 1-mm, 3-mm and 6-mm CMT compared to eyes without SRF (β = 104.7 [95% CI, 53.5; 156] µm, p < 0.001; β = 80.5 [95% CI, 45.9; 115.2] µm, p < 0.001; β = 55.1 [95% CI, 30.1; 80] µm, p < 0.001, respectively). Even though macular thickness was significantly associated with visual acuity, SRF was not associated (β = 0.127 [95% CI, -0.034; 0.287]; p = 0.12). However, in eyes with SRF, width (but not height) of the SRF was independently associated with lower visual acuity (β = 0.00017; [95% CI: 0.00003-0.00031]; p = 0.028).</p><p><strong>Conclusion: </strong>DME patients with SRF exhibited higher macular thickness compared to those without SRF, suggesting SRF is an anatomical marker of a more severe exudative process. However, SRF's independent impact on visual acuity was limited and modest in magnitude, suggesting further studies could improve our understanding of the pathophysiological and clinical significance of SRF in DME.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicenter Real-World Evaluation of Intravitreal Bevacizumab, Aflibercept, and Ranibizumab for Diabetic Macular Edema. 玻璃体内贝伐单抗、阿非利塞普和雷尼单抗治疗糖尿病黄斑水肿的多中心真实世界评估。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-10-08 DOI: 10.1159/oph/aeeag015
Efraim Berco, Orly Yakubovich Fink, Eilon Shcolnik, Michael Ostrovsky, Yuval Kozlov, Raman Tuli, Thomas Kin Man Lee, Ksenia Samocha, Shalhevet Goldfeather Ben Zaken, Nir Shoham-Hazon
{"title":"Multicenter Real-World Evaluation of Intravitreal Bevacizumab, Aflibercept, and Ranibizumab for Diabetic Macular Edema.","authors":"Efraim Berco, Orly Yakubovich Fink, Eilon Shcolnik, Michael Ostrovsky, Yuval Kozlov, Raman Tuli, Thomas Kin Man Lee, Ksenia Samocha, Shalhevet Goldfeather Ben Zaken, Nir Shoham-Hazon","doi":"10.1159/oph/aeeag015","DOIUrl":"10.1159/oph/aeeag015","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic macular edema (DME) is a significant cause of vision loss in patients with diabetic retinopathy, and treatment outcomes in routine clinical practice may differ from those reported in randomized clinical trials. We assessed the real-world effectiveness and treatment patterns of intravitreal bevacizumab, aflibercept (2 mg), and ranibizumab in patients newly diagnosed with DME.</p><p><strong>Methods: </strong>A retrospective, multicenter observational study with a 1-year follow-up was conducted at public clinics in Israel and Canada. A total of 309 eyes from 277 treatment-naive patients with DME were analyzed, including both eyes from 32 patients. Eyes were grouped by the first-line therapy: bevacizumab (n = 199), aflibercept 2 mg (n = 63), or ranibizumab (n = 47). The primary endpoint was change in visual acuity (VA) at 1 year. Secondary endpoints included change in central retinal thickness (CRT), injection frequency, final injection interval, and treatment response metrics. Generalized estimating equation (GEE) models were used to account for inter-eye correlation.</p><p><strong>Results: </strong>At 12 months, VA improved by 6 ETDRS letters with no significant difference between groups in the primary endpoint (p = 0.501). In adjusted GEE analyses using bevacizumab as the reference group, aflibercept and ranibizumab were associated with greater CRT reduction (-60.31 µm and -57.24 µm, respectively), longer final injection intervals (+3.52 and +2.58 weeks), and fewer injections over 12 months (-2.05 and -2.21; all p < 0.001). Aflibercept was also associated with lower odds of nonresponse (OR 0.08, p = 0.010), and both aflibercept and ranibizumab were associated with lower odds of non-extension (OR 0.08 and OR 0.02, respectively; both p < 0.001).</p><p><strong>Conclusion: </strong>In this real-world multicenter cohort, VA improved after anti-VEGF treatment, without a significant between-group difference in the primary visual endpoint. Aflibercept (2 mg) was associated with more favorable secondary anatomical and treatment-burden metrics in adjusted analyses. However, given center-determined treatment allocation and residual baseline CRT imbalance, these findings should be interpreted as exploratory real-world associations rather than definitive evidence of pharmacological superiority. These results highlight the gap between randomized trial efficacy and outcomes observed in routine clinical practice, supporting the need for further practice-based DME research.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration: Real-World Outcomes of a No-Loading-Dose Switching Protocol. Faricimab在先前治疗过的nAMD:无负载剂量切换方案的现实世界结果。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-09-10 DOI: 10.1159/oph/aeeag012
Scott Lenhof, Thibaud Mathis, Nicolas Lepretre, Jonathan Rencker, Laurent Kodjikian
{"title":"Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration: Real-World Outcomes of a No-Loading-Dose Switching Protocol.","authors":"Scott Lenhof, Thibaud Mathis, Nicolas Lepretre, Jonathan Rencker, Laurent Kodjikian","doi":"10.1159/oph/aeeag012","DOIUrl":"10.1159/oph/aeeag012","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the efficacy, anatomical outcomes, and safety of switching to faricimab without a loading dose, using a standardized institutional switch protocol, in patients with previously treated neovascular age-related macular degeneration (nAMD) who achieved a maximum fluid-free interval of 8 weeks or less with aflibercept or ranibizumab.</p><p><strong>Methods: </strong>This retrospective, single-center cohort study was conducted at Croix-Rousse Hospital, Lyon and included eyes with a maximum fluid-free interval of 8 weeks or less on aflibercept or ranibizumab, switched to faricimab between November 2023 and December 2024. Eyes were classified as poor responders (PRs) or frequent flyers (FFs) based on their prior anti-vascular endothelial growth factor response. No loading dose was administered. The primary outcome was a change in the last intended treatment interval. Secondary outcomes included best-corrected visual acuity (BCVA), spectral-domain optical coherence tomography parameters, predictors of interval extension, and safety.</p><p><strong>Results: </strong>128 eyes were included. Before switching, mean (standard deviation [SD]) treatment duration was 36.4 (21.9) months with a mean (SD) of 28.2 (17.0) intravitreal injections. After switching, the median gain in the last intended interval was 2.7 [IQR 2.1-3.3] weeks (p < 0.001). Subgroup analysis showed a median gain of 3.1 weeks in PRs (p < 0.001) and 2.4 weeks in FFs (p < 0.001). BCVA remained stable (p = 0.37). Significant reductions were observed in central macular thickness (p < 0.001), subretinal hyperreflective material (p = 0.02), intraretinal fluid (p < 0.001), and subretinal fluid (p < 0.001). Baseline characteristics were not associated with treatment interval extension. There was 1 case of anterior uveitis and vitritis, which resolved with topical corticosteroid treatment.</p><p><strong>Conclusion: </strong>In previously treated nAMD patients, switching to faricimab without a loading dose achieved meaningful treatment interval extension, potentially reducing treatment burden without compromising efficacy.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carbon Footprint of Outpatient Cataract Surgery in Germany: Multicentre Analysis of Emission Sources, Variability, and Opportunities for Transparent Reporting. 德国门诊白内障手术的碳足迹:多中心分析排放源、可变性和透明报告的机会。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-08-31 DOI: 10.1159/oph/aeeag011
Franka Wehrle, Hansjürgen Agostini, Karl Ulrich Bartz-Schmidt, H Burkhard Dick, Gerd Geerling, Adrian Gericke, Hans Hoerauf, Christoph Holtmann, Paul Kohlhas, Thabo Lapp, Norbert Pfeiffer, Berthold Seitz, Martin S Spitzer, Maria Steuernagel, Marcus W Storch, Suphi Taneri, Focke Ziemssen, Christian Girbardt
{"title":"Carbon Footprint of Outpatient Cataract Surgery in Germany: Multicentre Analysis of Emission Sources, Variability, and Opportunities for Transparent Reporting.","authors":"Franka Wehrle, Hansjürgen Agostini, Karl Ulrich Bartz-Schmidt, H Burkhard Dick, Gerd Geerling, Adrian Gericke, Hans Hoerauf, Christoph Holtmann, Paul Kohlhas, Thabo Lapp, Norbert Pfeiffer, Berthold Seitz, Martin S Spitzer, Maria Steuernagel, Marcus W Storch, Suphi Taneri, Focke Ziemssen, Christian Girbardt","doi":"10.1159/oph/aeeag011","DOIUrl":"10.1159/oph/aeeag011","url":null,"abstract":"<p><strong>Introduction: </strong>Outpatient cataract surgery is one of the most frequently performed surgical procedures worldwide. Reducing its carbon footprint without compromising hygiene and patient safety offers substantial potential for mitigating healthcare-related greenhouse gas emissions. This multicentre study quantified the carbon footprint of outpatient cataract surgery across ten heterogeneous German tertiary centres and examined intercentre variability in emissions as well as the extent to which current data support transparent, standardised reporting.</p><p><strong>Methods: </strong>Between December 2022 and March 2023, standardised on-site assessments collected data on staff and patient travel, electricity consumption, disposable material use, and waste generation. Data were converted into carbon dioxide equivalents (CO<sub>2</sub>e) using emission factors from national environmental agencies. Since detailed life cycle and sterilisation data could not be obtained for instrument manufacture and reprocessing, these components were modelled for all centres.</p><p><strong>Results: </strong>The centres showed substantial inter-site variation in all major emission categories. Disposable materials (2.53-8.30 kg CO<sub>2</sub>e) and sterilisation (2.62-7.13 kg CO<sub>2</sub>e) were the dominant contributors, together accounting for 56.6-84.6% of total emissions. Electricity use contributed 1.0%-18.5%, whereas waste disposal remained low (≤0.4%). Based on the combination of measured and modelled components, the estimated carbon footprint averaged 14.09 kg CO<sub>2</sub>e per cataract procedure (95% CI: 12.08-16.11 kg), with centre-level values ranging from 10.07 to 18.70 kg.</p><p><strong>Conclusion: </strong>Substantial emission reductions can be achieved by streamlining material use and improving sterilisation workflow. Transparent reporting that defines system boundaries, specifies uncertainties, and provides access to data collection methods is essential for comparability and for establishing reliable benchmarks in sustainable surgical practice. This study provides a comprehensive multicentre carbon footprint analysis for outpatient cataract surgery in Germany and offers a transparent framework that guides targeted reduction strategies.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13722464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantification of Straylight Induced by Silicone Oil Adherence and Calcification in Artisan Aphakia and Carlevale Intraocular Lenses. Artisan无晶状体和Carlevale人工晶状体中硅油附着和钙化引起的散光定量分析。
IF 2.3 4区 医学
Ophthalmologica Pub Date : 2026-08-28 DOI: 10.1159/oph/aeeag009
Leoni Britz, Niklas Junker, Agnieszka Zielinska, Fabian Jester, Jan Freudenberg, Uwe Bunz, Christian Scholz, Victor Aristide Augustin, Gerd Uwe Auffarth, Maximilian Hammer
{"title":"Quantification of Straylight Induced by Silicone Oil Adherence and Calcification in Artisan Aphakia and Carlevale Intraocular Lenses.","authors":"Leoni Britz, Niklas Junker, Agnieszka Zielinska, Fabian Jester, Jan Freudenberg, Uwe Bunz, Christian Scholz, Victor Aristide Augustin, Gerd Uwe Auffarth, Maximilian Hammer","doi":"10.1159/oph/aeeag009","DOIUrl":"10.1159/oph/aeeag009","url":null,"abstract":"<p><strong>Introduction: </strong>In lack of capsular support, two commonly used secondary intraocular lens (IOL) fixation strategies include retropupillary iris-claw fixation using the hydrophobic Artisan Aphakia and scleral fixation of the hydrophilic Carlevale IOL. Both models may come into direct contact with endotamponades frequently implanted in the same surgical procedure. The purpose of this laboratory study was to compare the interaction of both IOL models with endotamponades, specifically silicone oil adhesion and calcification, which is more prevalent after exposure to gas endotamponades.</p><p><strong>Methods: </strong>This laboratory study was conducted using Artisan Aphakia (Ophtec, Groningen, Netherlands), Carlevale IOL (Soleko IOL Division, Pontecorvo, Italy), and CT Spheris (Carls Zeiss Meditec, Jena, Germany) as a control. Straylight measurements were carried out with C-Quant straylight meter and used to quantify the effects of both, adherent silicone oil and calcifications in the polymer. Siluron 2000 was used to test silicone oil adhesion. Electrophoresis was used to induce IOL calcification. Calcification was quantified using thermogravimetric analysis and plasma optical emission spectroscopy. Light loss was evaluated using a power meter combined with an optical bench system. The reversibility of silicone oil adhesion was evaluated after usage of F4H5 as a cleansing solution.</p><p><strong>Results: </strong>The Artisan Aphakia was more prone to increased silicone oil adhesion causing a clinically relevant increase in straylight (baseline vs. silicone oil adherence: 3.0 vs. 140.7 deg2/sr; p = 0.002), not fully reversible by using F4H5 as a washout (baseline vs. F4H5 washout: 3.0 vs. 15.3 deg2/sr; p = 0.0019). In contrast, the Carlevale IOL demonstrated a higher susceptibility to calcification (baseline vs. calcification: 2.75 vs. 12.59 deg2/sr).</p><p><strong>Conclusion: </strong>In addition to clinical aspects, such as iris and ciliary body anatomy, the choice of endotamponade in trauma cases can influence the postoperative long-term optical quality of IOLs. Differences between hydrophilic and hydrophobic materials are magnified secondary IOL fixation due to the direct contact to the used endotamponade and should be evaluated during surgical planning.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书